Novo Nordisk A/s

Jacob Lund

Marie-Ange Buyse

Soren Steffensen

Evelyn De Tavernier

Frantisek Hubalek

Mathias Norrman

Andreas Vegge

Jais Rose Bjelke

Karina Thorn

Thomas Egebjerg

Per J Greisen

Mikkel Nors Harndahl

Philip Jonas Sassene

Daniele Granata

Simone Fulle

The present invention provides ISVD polypeptide derivatives capable of binding coagulation Factor IX(a) and Factor X(a) which are highly potent and provide a sufficiently long half-life such to allow for effective subcutaneous—as well as peroral administration. The ISVD polypeptides derivatives disclosed herein are thus suitable for treatment of haemophilia A, haemophilia A with inhibitors and acquired haemophilia A by various routes of administration including subcutaneous and peroral administration.

Highly potent ISVD compounds capable of substituting for FVIII(A)

The application relates to unique FX binding molecules, such as antibodies and fragments thereof which are useful in the treatment of haemophilia.

Factor X binders enhancing FX activation

Growing community of inventors

Roskilde, Denmark

Jacob Lund